Atara Biotherapeutics Stock News

Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q4 2021 Results - Earnings Call Transcript

Atara Biotherapeutics press release (NASDAQ:ATRA): Q4 GAAP EPS of -$0.96 misses by $0.37.Revenue of $7.55M misses by $27.59M.

Tab-cel U.S. BLA Submission Not Currently Expected for Q2 2022 as Further FDA Engagement and Alignment Required; Anticipated EU Approval On-Track for Q4 2022 Under Accelerated Assessment

Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -60% and 84.19%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Atara Biotherapeutics (NASDAQ:ATRA) is scheduled to announce Q4 earnings results on Monday, February 28th, after market close.The consensus EPS Estimate is -$0.69 (+27.4% Y/Y) and…

Atara Biotherapeutics (ATRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

A fatality in an early-stage clinical trial is weighing on the cell therapy company''s stock today.

Memorial Sloan Kettering Cancer Center''s (MSK) has notified the FDA of a fatal serious adverse event (SAE) associated with a patient in Phase 1 study of Atara Biotherapeutics Inc''s (NASDAQ: ATRA ) autologous mesothelin CAR T, ATA2271. MSK has voluntarily paused enrollment of new patients in the study temporarily while additional information regarding the case is gathered and reviewed. ATA2271 is an autologous chimeric antigen receptor (CAR) T-cell therapy targeting mesothelin … Full story available on Benzinga.com

(Reuters) - Atara Biotherapeutics Inc said on Friday that enrolment in an early-stage study of its experimental cancer therapy had been paused after a patient died, sending shares of the drug developer down 12%. The trial testing the CAR-T cell therapy, ATA2271, was voluntarily paused by Atara''s partner, Memorial Sloan Kettering Cancer Center in New York, after a fatal serious adverse event. Atara said the institute has notified the U.S. Food and Drug Administration and is gathering more information about the case, with more updates expected in the coming weeks. CAR-T therapies work by harvesting a patient''s own disease-fighting T-cells, genetically engineering them to target specific proteins on cancer cells, and replacing them to seek out and attack cancer. The company said the first six patients enrolled in the two lowest dose groups had no serious toxicities that prevented an increase in dosage, and the patient who died was the first in a third, higher-dose cohort. (Reporting by Leroy Leo in Bengaluru; Editing by Amy Caren Daniel)

Atara (ATRA) is trading ~12% lower in the pre-market on Friday after the company reported a fatal serious adverse event (SAE) in a patient who received its experimental chimeric…

Memorial Sloan Kettering Cancer Center's (MSK) has notified the FDA of a fatal serious adverse event (SAE) associated with a patient in Phase 1 study of Atara Biotherapeutics Inc's (NASDAQ: ATRA)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release fourth quarter and full year 2021 financial results after market close on Monday, February 28, 2022. Following the release, the Company will host a live conference call and we